## Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 4

## VALEANT PHARMACEUTICALS INTERNATIONAL

Form 4 May 19, 2009

# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

if no longer subject to Section 16. Form 4 or Form 5

Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person \* ValueAct Holdings, L.P.

(First)

(Street)

(Middle)

2. Issuer Name and Ticker or Trading Symbol

Issuer (Check all applicable)

VALEANT PHARMACEUTICALS INTERNATIONAL [VRX]

3. Date of Earliest Transaction

(Month/Day/Year) 05/15/2009

Director Officer (give title

\_X\_\_ 10% Owner \_X\_ Other (specify

below)

See remarks below

**OMB APPROVAL** 

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

**OMB** 

Number:

Expires:

response...

435 PACIFIC AVENUE, 4TH **FLOOR** 

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

5. Relationship of Reporting Person(s) to

Applicable Line)

Form filed by One Reporting Person \_X\_ Form filed by More than One Reporting

Person

below)

SAN FRANCISCO, CA 94133

							Cison		
(City)	(State)	(Zip) Tabl	le I - Non-l	Derivative	Secur	ities Acq	uired, Disposed o	f, or Beneficial	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired ction(A) or Disposed of (D) (Instr. 3, 4 and 5)  (A) or			5. Amount of Securities Ownership Beneficially Form: Direct Owned (D) or Following Indirect (I) Reported (Instr. 4) Transaction(s) (Instr. 3 and 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(D)	Price	(IIIstr. 3 and 4)		
Common Stock, par value \$.01 per share	05/15/2009		P	3,075	A	\$ 19.82	15,780,004	I	See footnotes (1) (2)
Common Stock, par value \$.01 per share	05/15/2009		P	19,989	A	\$ 19.75	15,799,993	I	See footnotes (1) (2)
Common Stock, par value \$.01	05/15/2009		P	33,200	A	\$ 19.89	15,833,193	I	See footnotes (1) (2)

## Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 4

per share

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 9. Nu Deriv Secur Bene Own Follo Repo Trans

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of lying	8. Price o Derivativ Security (Instr. 5)
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

# **Reporting Owners**

Reporting Owner Name / Address	Relationships						
and the state of t	Director	10% Owner	Officer	Other			
ValueAct Holdings, L.P. 435 PACIFIC AVENUE, 4TH FLOOR SAN FRANCISCO, CA 94133		X		See remarks below			
VA Partners I, LLC 435 PACIFIC AVENUE, 4TH FLOOR SAN FRANCISCO, CA 94133		X		See remarks below			
ValueAct Capital Management, L.P. 435 PACIFIC AVENUE, 4TH FLOOR SAN FRANCISCO, CA 94133		X		See remarks below			
ValueAct Capital Management, LLC 435 PACIFIC AVENUE, 4TH FLOOR SAN FRANCISCO, CA 94133		X		See remarks below			
ValueAct Holdings GP, LLC 435 PACIFIC AVENUE, 4TH FLOOR SAN FRANCISCO, CA 94133		X		See remarks below			

Reporting Owners 2

# **Signatures**

VALUEACT HOLDINGS, L.P., By: VALUEACT HOLDINGS GP, LLC, its General

Partner, By:/s/ George F. Hamel. Jr., Chief Operating Officer

05/19/2009 Date

\*\*Signature of Reporting Person

VALUEACT CAPITAL MASTER FUND, L.P., By: VA PARTNERS I, LLC, its General

Partner, By:/s/ George F. Hamel. Jr., Chief Operating Officer

05/19/2009

\*\*Signature of Reporting Person

Date

VA PARTNERS I, LLC, By:/s/ George F. Hamel. Jr., Chief Operating Officer

05/19/2009

\*\*Signature of Reporting Person

Date

VALUEACT CAPITAL MANAGEMENT, L.P., By: VALUEACT CAPITAL

MANAGEMENT, LLC, its General Partner, By:/s/ George F. Hamel. Jr., Chief Operating Officer

05/19/2009

\*\*Signature of Reporting Person

Date

VALUEACT CAPITAL MANAGEMENT, LLC, By:/s/ George F. Hamel. Jr., Chief

Operating Officer

05/19/2009

\*\*Signature of Reporting Person

Date

VALUEACT HOLDINGS GP, LLC, By:/s/ George F. Hamel. Jr., Chief Operating Officer

05/19/2009

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The securities reported herein are directly beneficially owned by ValueAct Capital Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) VA Partners I, LLC as General Partner of ValueAct Capital Master Fund, L.P., (ii) ValueAct

- (1) Capital Management, L.P. as the manager of ValueAct Capital Master Fund, L.P., (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P.
  - Each reporting person listed herein disclaims beneficial ownership of the reported securities except to the extent of its pecuniary
- (2) interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

#### **Remarks:**

The reporting persons herein may be deemed to be members of a "group" for purposes of the Securities Exchange Act of 1934

G. Mason Morfit, a member of the management board of ValueAct Holdings GP, LLC, serves on the board of directors of the

Joint Filer Information:

Name: ValueAct Capital Master Fund, L.P.

Address: 435 Pacific Avenue, 4th Floor, San Francisco, CA 94133

Designated Filer: ValueAct Holdings, L.P.

Issuer and Ticker: Valeant Pharmaceuticals International (VRX)

Date of Event Requiring Statement: 05/15/2009

Signatures 3

#### Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 4

Name: VA Partners I, LLC

Address: 435 Pacific Avenue, 4th Floor, San Francisco, CA 94133

Designated Filer: ValueAct Holdings, L.P.

Issuer and Ticker: Valeant Pharmaceuticals International (VRX)

Date of Event Requiring Statement: 05/15/2009

Name: ValueAct Capital Management, L.P.

Address: 435 Pacific Avenue, 4th Floor, San Francisco, CA 94133

Designated Filer: ValueAct Holdings, L.P.

Issuer and Ticker: Valeant Pharmaceuticals International (VRX)

Date of Event Requiring Statement: 05/15/2009

Name: ValueAct Capital Management, LLC

Address: 435 Pacific Avenue, 4th Floor, San Francisco, CA 94133

Designated Filer: ValueAct Holdings, L.P.

Issuer and Ticker: Valeant Pharmaceuticals International (VRX)

Date of Event Requiring Statement: 05/15/2009

Name: ValueAct Holdings GP, LLC

Address: 435 Pacific Avenue, 4th Floor, San Francisco, CA 94133

Designated Filer: ValueAct Holdings, L.P.

Issuer and Ticker: Valeant Pharmaceuticals International (VRX)

Date of Event Requiring Statement: 05/15/2009

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.